炎症性肠病患者生物制剂家庭输注与医院输注的比较
该研究比较炎症性肠病患者接受生物制剂家庭输注与医院输注中心输注的不良结局,主要结局为停止治疗、IBD相关急诊就诊或IBD相关住院的复合终点。原文仅报告研究目的,未给出具体结果数据。
要点
- 研究比较IBD患者生物制剂家庭输注与医院输注中心输注的不良结局。
- 主要结局为停止治疗、IBD相关急诊就诊或IBD相关住院的复合终点。
- 原文仅描述研究目的,未报告具体结果数据。
核心结论
- 原文未报告研究结论。
研究设计与样本
- 研究比较接受家庭输注或医院输注中心输注生物制剂的炎症性肠病患者的不良结局。
主要发现
- 原文未报告具体研究结果。
关键数值与推荐
- 主要结局为不良结局复合终点,定义为停止治疗、IBD相关急诊就诊或IBD相关住院。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammatory bowel disease (IBD) therapy often requires biologic medications delivered by intravenous infusion.1-4 Historically, intravenous infusions of infliximab and vedolizumab in patients with IBD were delivered under direct supervision of clinicians in infusion centers at hospitals or clinics. Recently, intravenous infusions have transitioned into patient homes. Professional societies have differed on their recommendations for biologic home infusions (HI),5,6 yet limited data exist on the safety and efficacy of HI programs.7,8 Therefore, the primary aim of this study was to compare adverse outcomes (AOs), as defined as a composite of stopping therapy, IBD-related emergency-room (ER) visit, or IBD-related hospitalization, in patients with IBD receiving biologics as HI or at a hospital-based infusion center.
引用
- Fenster M, Ungaro RC, Hirten R, et al. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019. PMID: 30910602. doi:10.1016/j.cgh.2019.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。